BEAM Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

13.54M

-54.98%

-1.117

+2.43%

15.62M

+109.08%

-1.153

-7.05%

15.77M

+86.28%

-1.179

+17.94%

Estimates Revision

The market is revising Downward the revenue expectations for Beam Therapeutics Inc. (BEAM) for FY2025, with the revenue forecasts being adjusted by -13.1% over the past three months. During the same period, the stock price has changed by 0.32%.

Revenue Estimates for FY2025

Revise Downward

-13.1%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+1.94%

In Past 3 Month

Stock Price

Go Up

+0.32%

In Past 3 Month

13 Analyst Rating

Wall Street analysts forecast BEAM stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for BEAM is 41.90 USD with a low forecast of 21.00 USD and a high forecast of 80.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

11 Buy

2 Hold

0 Sell

Strong Buy

Current: 0.000

Low

21.00

Averages

41.90

High

80.00

Current: 0.000

Low

21.00

Averages

41.90

High

80.00

UBS

Michael Yee

Neutral

initiated

$28

2026-01-07

New

Reason

UBS

Michael Yee

Price Target

$28

2026-01-07

New

initiated

Neutral

Reason

UBS analyst Michael Yee initiated coverage of Beam Therapeutics (BEAM) with a Neutral rating and $28 price target as the analyst initiated or assumed coverage on 22 small-to-mid cap biotech names. After a rough period, biotech fundamentals are now inflecting, contends the analyst, who expects investor confidence to recover and sees this positioning biotech for strong performance in 2026. Among the group, top picks include Apogee Therapeutics (APGE), Cogent Biosciences (COGT), Kodiak Sciences (KOD), Ideaya Biosciences (IDYA), Inventiva (IVA), SAB Biotherapeutics (SABS) and Ventyx Biosciences (VTYX), which the analyst highlights as having key upcoming catalysts, de-risked best-in-class portfolios, strong data, and broader pipelines.

BofA

Alec Stranahan

Buy

maintain

$43 -> $45

2026-01-06

New

Reason

BofA

Alec Stranahan

Price Target

$43 -> $45

2026-01-06

New

maintain

Buy

Reason

BofA analyst Alec Stranahan raised the firm's price target on Beam Therapeutics to $45 from $43 and keeps a Buy rating on the shares. The firm is updating its price targets for U.S Biopharmaceuticals under its coverage, the analyst tells investors. Over the past few months, several key items "have fallen into place," including positive data catalysts being rewarded; large-cap biopharma spending cash on M&A and in-licensing; growing backlog of companies on the private side; improving access to capital; and limited impact from drug price regulation, BofA says. The firm believes biotech is back, but the biggest concern is whether this will last.

Evercore ISI

Outperform

initiated

$35

2025-11-24

Reason

Evercore ISI

Price Target

$35

2025-11-24

initiated

Outperform

Reason

Evercore ISI initiated coverage of Beam Therapeutics with an Outperform rating and $35 price target. BEAM-302 offers "a potentially game-changing approach for AATD," with early data showing impressive levels of corrected AAT production, says the analyst, who calls upcoming data due in Q1 of 2026 "crucial."

Clear Street

Buy

maintain

$34 -> $37

2025-11-04

Reason

Clear Street

Price Target

$34 -> $37

2025-11-04

maintain

Buy

Reason

Clear Street raised the firm's price target on Beam Therapeutics to $37 from $34 and keeps a Buy rating on the shares following the Q3 report. BEAM-103 has dosed the first patient in a healthy volunteer study while the next major catalyst for the shares being the interim update from BEAM-302 in early 2026, the analyst tells investors in a research note. Clear adds that Beam owns 17% of private company Orbital Therapeutics, which amounts to $255M in its recently announced takeout.

Wedbush

David Nierengarten

Neutral

downgrade

$14 -> $9

2025-10-30

Reason

Wedbush

David Nierengarten

Price Target

$14 -> $9

2025-10-30

downgrade

Neutral

Reason

Wedbush analyst David Nierengarten lowered the firm's price target on Intellia Therapeutics (NTLA) to $9 from $14 and keeps a Neutral rating on the shares. The firm notes FDA placed a clinical hold on the Phase 3 MAGNITUDE and MAGNITUDE-2 trials of nex-z following a voluntary pause due to new safety signals of symptomatic transaminase elevation and bilirubin increase. A formal Clinical Hold Letter will be provided within 30 days. Wedbush reiterates its position that these safety signals appear target-specific rather than a class effect of LNP delivery, and views recent price action for Beam Therapeutics (BEAM) and Prime Medicine (PRME) as a buying opportunity. For Intellia's nex-z, even after the clinical hold is resolved, the firm expects reduced market uptake against competing siRNA therapies, which do not have substantial reports of hepatic toxicity and can be discontinued in the case of adverse events.

HC Wainwright & Co.

Patrick Trucchio

Strong Buy

Reiterates

$80

2025-04-07

Reason

HC Wainwright & Co.

Patrick Trucchio

Price Target

$80

2025-04-07

Reiterates

Strong Buy

Reason

Valuation Metrics

The current forward P/E ratio for Beam Therapeutics Inc (BEAM.O) is -5.84, compared to its 5-year average forward P/E of -10.51. For a more detailed relative valuation and DCF analysis to assess Beam Therapeutics Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-10.51

Current PE

-5.84

Overvalued PE

-2.72

Undervalued PE

-18.31

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-8.53

Current EV/EBITDA

-3.35

Overvalued EV/EBITDA

0.65

Undervalued EV/EBITDA

-17.71

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

113.85

Current PS

44.02

Overvalued PS

250.95

Undervalued PS

-23.24

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areBuying! The buying amount has increased 161.22% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

Bought

BEAM News & Events

Events Timeline

No data

News

8.0

01-06NASDAQ.COM

BEAM Options Analysis: $29 Put Contract Offers 10.17% YieldBoost

9.5

01-06Benzinga

U.S. Stocks Rise as Microchip Technology Raises Q3 Revenue Outlook to $1.185 Billion

7.5

2025-12-31Benzinga

ARK Invest Increases Holdings in Gene Editing Firms, PACB Stock Rises

People Also Watch

Frequently Asked Questions

What is Beam Therapeutics Inc (BEAM) stock price today?

The current price of BEAM is 27.96 USD — it has decreased -0.14 % in the last trading day.

What is Beam Therapeutics Inc (BEAM)'s business?

Beam Therapeutics Inc. is a biotechnology company developing precision genetic medicines through base editing. The Company's suite of gene editing technologies is anchored by base editing, a technology that is designed to enable precise, predictable and efficient single base changes, at targeted genomic sequences, without making double-stranded breaks in the deoxyribonucleic acid. Its lead programs are focused on sickle cell disease and alpha-1 antitrypsin deficiency, and it is also advancing programs in other genetic diseases. Its primary programs include BEAM-101, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-302 and BEAM-301. BEAM-101 is a patient-specific, autologous hematopoietic stem cell (HSC), investigational therapy. ESCAPE is a potentially non-genotoxic approach to HSC transplantation. BEAM-302 is a liver-targeting lipid nanoparticle formulation of base editing reagents designed to offer a one-time treatment to correct the E342K point mutation (PiZZ genotype).

What is the price predicton of BEAM Stock?

What is Beam Therapeutics Inc (BEAM)'s revenue for the last quarter?

Beam Therapeutics Inc revenue for the last quarter amounts to 9.70M USD, decreased -32.03 % YoY.

What is Beam Therapeutics Inc (BEAM)'s earnings per share (EPS) for the last quarter?

Beam Therapeutics Inc. EPS for the last quarter amounts to -1.10 USD, decreased -5.98 % YoY.

What changes have occurred in the market's expectations for Beam Therapeutics Inc (BEAM)'s fundamentals?

How many employees does Beam Therapeutics Inc (BEAM). have?

Beam Therapeutics Inc (BEAM) has 483 emplpoyees as of January 09 2026.

What is Beam Therapeutics Inc (BEAM) market cap?

Today BEAM has the market capitalization of 2.84B USD.